Evidence map›Paper›PMID 41404351›Full record

ArticleNeurology. Genetics2026

Identification of Intronic Variants in

Kohta Nakamura, Yoshihito Kishita, Ayumu Sugiura, Kokoro Ozaki, Yukiko Yatsuka, Naoyuki Matsumoto, Atsuko Okazaki, Holger Prokisch, Koichi Maruyama, Hiroyasu Iwasa and 5 more

Abstract read
In one paragraph

Article in Neurology. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kohta NakamuraDiagnostics and Therapeutics of Intractable Disease, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0009-0009-9109-7250
Yoshihito KishitaDiagnostics and Therapeutics of Intractable Disease, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4978-1680
Ayumu SugiuraDiagnostics and Therapeutics of Intractable Disease, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4776-1478
Kokoro OzakiDiagnostics and Therapeutics of Intractable Disease, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9081-8348
Yukiko YatsukaDiagnostics and Therapeutics of Intractable Disease, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3137-6919
Naoyuki MatsumotoDiagnostics and Therapeutics of Intractable Disease, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8689-7645
Atsuko OkazakiDiagnostics and Therapeutics of Intractable Disease, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7517-2881
Holger ProkischInstitute of Neurogenomics, Computational Health Center, Helmholtz Zentrum München, Neuherberg, Germany.ORCID https://orcid.org/0000-0003-2379-6286
Koichi MaruyamaDepartment of Pediatric Neurology, Aichi Developmental Disability Center Central Hospital, Aichi, Japan.ORCID https://orcid.org/0000-0003-4830-7303
Hiroyasu IwasaDepartment of General Medicine, Aichi Developmental Disability Center Central Hospital, Aichi, Japan.ORCID https://orcid.org/0000-0002-6800-2438
Kei MurayamaDiagnostics and Therapeutics of Intractable Disease, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-3923-8636
Hiroshi MatsumotoDepartment of Pediatrics, Saitama Medical University, Saitama, Japan.ORCID https://orcid.org/0000-0002-0166-3469
Akira OhtakeDepartment of Pediatrics, Saitama Medical University, Saitama, Japan.ORCID https://orcid.org/0000-0003-1147-3113
Yuichi ShiraishiDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0001-6144-5845
Yasushi OkazakiDiagnostics and Therapeutics of Intractable Disease, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3241-5502

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Leigh syndrome is an important manifestation of childhood-onset primary mitochondrial disease. Panel sequencing and whole exome sequencing are cost-effective for diagnosing mitochondrial diseases; however, more than half of mitochondrial disease cases remain genetically undiagnosed. This study aimed to demonstrate that combining whole genome sequencing (WGS) and RNA sequencing (RNA-seq) analyses can identify disease-causing variants that would otherwise be missed. Methods: We performed WGS and RNA-seq on a patient with Leigh syndrome. Chromosomal phasing using Sanger sequencing of parental and patient blood samples was conducted to confirm compound heterozygous variants. RNA-seq data were analyzed for splicing abnormalities. Overexpression studies of wild-type Results: We discovered compound heterozygous intronic variants (c.86-16_86-15del in intron2 and c.164-362G>A in intron3) of the Discussion: This study highlights the importance of combining WGS and RNA-seq and provides new insights into detecting abnormalities in deep intronic regions, particularly those involving mobile elements, such as Alu. This approach can play a crucial role in identifying genetic variations and elucidating transcriptional control mechanisms that are not readily achieved by conventional methods, especially in the context of mobile element-induced complexities.

Identifiers

PMID41404351
PMCPMC12703898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.